News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
869,643 Results
Type
Article (87941)
Company Profile (825)
Press Release (780861)
Multimedia
Podcasts (194)
Webinars (28)
Section
Business (233256)
Career Advice (4146)
Deals (39874)
Drug Delivery (150)
Drug Development (91409)
Employer Resources (204)
FDA (18382)
Job Trends (17426)
News (397891)
Policy (39966)
Tag
Academia (3010)
Academic (2)
Accelerated approval (34)
Adcomms (36)
Allergies (145)
Alliances (56981)
ALS (180)
Alzheimer's disease (1786)
Antibody-drug conjugate (ADC) (342)
Approvals (18556)
Artificial intelligence (618)
Autoimmune disease (155)
Automation (35)
Bankruptcy (406)
Best Places to Work (12634)
BIOSECURE Act (23)
Biosimilars (199)
Biotechnology (490)
Bladder cancer (162)
Brain cancer (65)
Breast cancer (653)
Cancer (4975)
Cardiovascular disease (437)
Career advice (3569)
Career pathing (41)
CAR-T (302)
CDC (59)
Celiac Disease (1)
Cell therapy (819)
Cervical cancer (37)
Clinical research (76943)
Collaboration (1776)
Company closure (5)
Compensation (1141)
Complete response letters (70)
COVID-19 (2989)
CRISPR (98)
C-suite (840)
Cystic fibrosis (154)
Data (6188)
Decentralized trials (2)
Denatured (71)
Depression (149)
Diabetes (528)
Diagnostics (7217)
Digital health (44)
Diversity (13)
Diversity, equity & inclusion (49)
Drug discovery (298)
Drug pricing (221)
Drug shortages (36)
Duchenne muscular dystrophy (234)
Earnings (100075)
Editorial (63)
Employer branding (25)
Employer resources (173)
Events (135012)
Executive appointments (1028)
FDA (21505)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (24)
Funding (1540)
Gene editing (212)
Generative AI (63)
Gene therapy (662)
GLP-1 (1113)
Government (5436)
Grass and pollen (8)
Guidances (383)
Healthcare (20942)
HIV (60)
Huntington's disease (48)
IgA nephropathy (86)
Immunology and inflammation (288)
Immuno-oncology (57)
Indications (86)
Infectious disease (3275)
Inflammatory bowel disease (203)
Inflation Reduction Act (17)
Influenza (118)
Intellectual property (242)
Interviews (816)
IPO (17954)
IRA (60)
Job creations (5199)
Job search strategy (2866)
JPM (64)
Kidney cancer (17)
Labor market (91)
Layoffs (659)
Leadership (40)
Legal (10159)
Liver cancer (98)
Longevity (14)
Lung cancer (676)
Lymphoma (374)
Machine learning (44)
Management (66)
Manufacturing (832)
MASH (172)
Medical device (15014)
Medtech (15061)
Mergers & acquisitions (22968)
Metabolic disorders (1376)
Multiple sclerosis (160)
NASH (23)
Neurodegenerative disease (349)
Neuropsychiatric disorders (95)
Neuroscience (3085)
Neurotech (1)
NextGen: Class of 2026 (7707)
Non-profit (5110)
Now hiring (64)
Obesity (663)
Opinion (332)
Ovarian cancer (165)
Pain (202)
Pancreatic cancer (229)
Parkinson's disease (292)
Partnered (39)
Patents (496)
Patient recruitment (465)
Peanut (60)
People (66852)
Pharmaceutical (145)
Pharmacy benefit managers (32)
Phase I (23781)
Phase II (33380)
Phase III (25167)
Pipeline (4820)
Policy (332)
Postmarket research (3554)
Preclinical (10688)
Press Release (72)
Prostate cancer (241)
Psychedelics (53)
Radiopharmaceuticals (298)
Rare diseases (878)
Real estate (7439)
Recruiting (80)
Regulatory (28930)
Reports (66)
Research institute (2722)
Resumes & cover letters (651)
Rett syndrome (27)
RNA editing (20)
RSV (83)
Schizophrenia (157)
Series A (256)
Series B (194)
Service/supplier (30)
Sickle cell disease (103)
Special edition (27)
Spinal muscular atrophy (176)
Sponsored (48)
Startups (4333)
State (2)
Stomach cancer (20)
Supply chain (112)
Tariffs (99)
The Weekly (121)
Vaccines (1139)
Venture capital (94)
Weight loss (457)
Women's health (85)
Worklife (21)
Date
Today (50)
Last 7 days (389)
Last 30 days (2070)
Last 365 days (33022)
2026 (1954)
2025 (33228)
2024 (38142)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51337)
2018 (39122)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1290)
Alabama (88)
Alaska (7)
Arizona (340)
Arkansas (14)
Asia (51520)
Australia (9045)
California (11409)
Canada (3284)
China (1147)
Colorado (484)
Connecticut (496)
Delaware (343)
Europe (118360)
Florida (1667)
Georgia (368)
Hawaii (3)
Idaho (68)
Illinois (956)
India (66)
Indiana (540)
Iowa (24)
Japan (418)
Kansas (133)
Kentucky (42)
Louisiana (29)
Maine (83)
Maryland (1447)
Massachusetts (8423)
Michigan (354)
Minnesota (662)
Mississippi (6)
Missouri (139)
Montana (35)
Nebraska (29)
Nevada (124)
New Hampshire (85)
New Jersey (3079)
New Mexico (33)
New York (3021)
North Carolina (1594)
North Dakota (10)
Northern California (5446)
Ohio (349)
Oklahoma (22)
Oregon (54)
Pennsylvania (2286)
Puerto Rico (21)
Rhode Island (50)
South America (1658)
South Carolina (64)
South Dakota (1)
Southern California (4398)
Tennessee (174)
Texas (1802)
United States (41245)
Utah (342)
Vermont (1)
Virginia (285)
Washington D.C. (87)
Washington State (960)
West Virginia (4)
Wisconsin (125)
Wyoming (2)
There are 869,643 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
SpectronRx Accelerates Commercial Growth with Major Expansion of Its Grissom Aeroplex Manufacturing Campus
The 34-acre site now supports 200,000 square feet of GMP radiopharmaceutical production, with scalable capacity exceeding one million square feet
January 23, 2026
·
1 min read
Immunology and inflammation
Sanofi Stumbles Again in Eczema—But Plans FDA Filing for OX40 Blocker Anyway
The mixed data from the Phase III COAST 2 trial follows an underwhelming data drop from COAST 1 in September that Leerink Partners said “fell well below expectations.”
January 23, 2026
·
2 min read
·
Tristan Manalac
Press Releases
MustGrow Closes $2.0 Million Non-Brokered LIFE Offering
January 23, 2026
·
5 min read
Press Releases
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million
January 23, 2026
·
6 min read
Government
Spending Bill Clears House, Keeping Priority Review Voucher Hopes Alive
The $1.2 trillion budget package will now move to the Senate, which is expected to hold a vote next week.
January 23, 2026
·
3 min read
·
Tristan Manalac
Rare diseases
Rare Disease Vouchers Caught in Political Abyss. It Didn’t Have To Be This Way
The FDA’s rare pediatric disease priority review voucher program missed reauthorization at the last minute in 2024; advocates have been fighting to get it back ever since.
January 23, 2026
·
3 min read
·
Heather McKenzie
Funding
China’s Corxel Nabs $287M Series D1 to Bankroll GLP-1 Pill
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
January 23, 2026
·
1 min read
·
Tristan Manalac
Vaccines
Moderna Won’t Run Phase III Vaccine Trials as Skepticism Grows in US: Bloomberg
Growing opposition to vaccines in the U.S., driven by recent government policy changes, makes it difficult to see a return on investment in vaccine development, Moderna CEO Stéphane Bancel said this week.
January 23, 2026
·
2 min read
·
Tristan Manalac
Vaccines
ACIP Chair Questions Polio Vaccines, Values Individual Choice Over Public Benefit
“I don’t like established science,” ACIP chairperson Kirk Milhoan said in an interview on the Why Should I Trust You? podcast. “Science is what I observe.”
January 23, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Aptar Declares Quarterly Dividend and Announces 2026 Annual Meeting Details
January 23, 2026
·
2 min read
1 of 86,965
Next
